Company: NCNA
Filing Date: 2025-04-24
Form Type: DRSLTR
Source: 0000950123-25-003671
Chunk: 0

Company: NuCana plc
Filing Date: 2025-04-24
Form: DRSLTR
Chunk 0
---
| One Financial Center 
 Boston, MA 02111     
 617 542 6000         
 mintz.com            |

April 23, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky and Tim Buchmiller

Ladies and Gentlemen: We are submitting this letter on behalf of NuCana plc (the “ Company”) in response to the comments from the staff (the “ Staff”) of the U.S. Securities and Exchange Commission (the “ Commission”) received by letter dated April 17, 2025 (the “ Comment Letter”) from the Division of Corporation Finance, Office of Life Sciences, to Hugh S. Griffith, Chief Executive Officer of the Company, relating to the above-referenced Draft Registration Statement on Form F-1.In conjunction with this letter, the Company is filing a Registration Statement on Form F-1with the Commission (the “ Form F-1”). For reference, we have set forth below in italics the Staff’s comments from the Comment Letter and have keyed the Company’s responses to the numbering of the comments and the headings used in the Comment Letter. Where appropriate, the Company has responded to the Staff’s comments by making changes to the disclosure in the Form F-1.Page numbers referred to in the responses reference the applicable pages of Form F-1. Draft Registration Statement on Form F-1 Cover Page Comment 1: We note your disclosure on page 10 that the Series A Warrants and Series B Warrants contain reset provisions that may result in a downward adjustment to the exercise price of such warrants, and that may result in a corresponding increase to the number of ADSs issuable upon the exercise of such warrants, and that, additionally, if the Series B Warrants are exercised by way of an “alternative cashless exercise,” such exercising holder will receive three ADSs for each ADS they would receive in a cash exercise for the Series B Warrants they exercise, without any cash payment to the company (subject to the mandatory nominal exercise price). Please revise the cover page headings, the cover page narrative and the Prospectus Summary to highlight the maximum number of ADSs that could be issued upon the exercise of your Series A Warrants and Series B Warrants, and, if similar formulas apply, the Pre-FundedWarrants. For guidance, refer to Regulation S-KItem 501(b)(2). Additionally, as appropriate for each